JP2023524092A - 抗デクチン-2抗体 - Google Patents

抗デクチン-2抗体 Download PDF

Info

Publication number
JP2023524092A
JP2023524092A JP2022566470A JP2022566470A JP2023524092A JP 2023524092 A JP2023524092 A JP 2023524092A JP 2022566470 A JP2022566470 A JP 2022566470A JP 2022566470 A JP2022566470 A JP 2022566470A JP 2023524092 A JP2023524092 A JP 2023524092A
Authority
JP
Japan
Prior art keywords
seq
dectin
binding agent
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524092A5 (cg-RX-API-DMAC7.html
Inventor
エリン アッカーマン、シェリー
ドーナン、デイヴィッド
エー. ヘニング、カーラ
エー. ケンケル、ジャスティン
Original Assignee
ボルト バイオセラピューティクス、インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボルト バイオセラピューティクス、インコーポレーテッド filed Critical ボルト バイオセラピューティクス、インコーポレーテッド
Publication of JP2023524092A publication Critical patent/JP2023524092A/ja
Publication of JP2023524092A5 publication Critical patent/JP2023524092A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022566470A 2020-05-01 2021-05-03 抗デクチン-2抗体 Pending JP2023524092A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01
US63/018,952 2020-05-01
PCT/US2021/030466 WO2021222894A1 (en) 2020-05-01 2021-05-03 Anti-dectin-2 antibodies

Publications (2)

Publication Number Publication Date
JP2023524092A true JP2023524092A (ja) 2023-06-08
JP2023524092A5 JP2023524092A5 (cg-RX-API-DMAC7.html) 2024-05-16

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566470A Pending JP2023524092A (ja) 2020-05-01 2021-05-03 抗デクチン-2抗体

Country Status (13)

Country Link
US (3) US11753474B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524092A (cg-RX-API-DMAC7.html)
KR (1) KR20230005907A (cg-RX-API-DMAC7.html)
CN (1) CN115461122A (cg-RX-API-DMAC7.html)
AU (1) AU2021262828A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175576A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003012A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220582A (cg-RX-API-DMAC7.html)
IL (1) IL297782A (cg-RX-API-DMAC7.html)
MX (1) MX2022013616A (cg-RX-API-DMAC7.html)
WO (1) WO2021222894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145993B2 (en) * 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024216089A1 (en) * 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2019006038A1 (en) * 2017-06-28 2019-01-03 The Board Of Trustees Of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR STIMULATING DECTINE 2 AND CANCER IMMUNOTHERAPY

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US7071171B1 (en) * 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
SG11202110663UA (en) 2019-04-05 2021-10-28 Dren Bio Inc Methods of depleting disease causing agents via antibody targeted phagocytosis
EP4225373A4 (en) 2020-10-07 2025-01-08 Dren Bio, Inc. ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2019006038A1 (en) * 2017-06-28 2019-01-03 The Board Of Trustees Of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR STIMULATING DECTINE 2 AND CANCER IMMUNOTHERAPY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "HUMAN DECTIN-2/CLEC6A ANTIBODY", R&D SYSTEMS, JPN5023008598, 14 March 2020 (2020-03-14), pages 1 - 2, ISSN: 0005792880 *
MATTHEW W PARSONS; ET AL: "DECTIN-2 REGULATES THE EFFECTOR PHASE OF HOUSE DUST MITE-ELICITED PULMONARY 以下備考", THE JOURNAL OF IMMUNOLOGY, vol. VOL:192, NR:4, JPN5023008600, 15 February 2014 (2014-02-15), US, pages 1361 - 1371, ISSN: 0005792881 *

Also Published As

Publication number Publication date
CR20220582A (es) 2023-01-09
BR112022020639A2 (pt) 2022-11-29
CN115461122A (zh) 2022-12-09
EP4142881A1 (en) 2023-03-08
CA3175576A1 (en) 2021-11-04
US20220153849A1 (en) 2022-05-19
US11753474B2 (en) 2023-09-12
MX2022013616A (es) 2022-11-16
IL297782A (en) 2022-12-01
US12325750B2 (en) 2025-06-10
CL2022003012A1 (es) 2023-06-23
KR20230005907A (ko) 2023-01-10
WO2021222894A1 (en) 2021-11-04
US20230406939A1 (en) 2023-12-21
US20250270329A1 (en) 2025-08-28
AU2021262828A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP7323659B2 (ja) ヘテロ二量体タンパク質
US11547761B1 (en) Antibody adjuvant conjugates
US11149094B2 (en) Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
EP3609540B1 (en) Immunoconjugate synthesis method
JP6952605B2 (ja) 多特異性抗原結合タンパク質
CA2906927C (en) Modulation of t cells with bispecific antibodies and fc fusions
CN105051069B (zh) 新型异二聚体蛋白
US12325750B2 (en) Anti-Dectin-2 antibodies and methods of using
JP2021524447A (ja) イムノコンジュゲート
CN110290810A (zh) 抗体佐剂缀合物
RU2727012C2 (ru) Получение гетеромультимерных белков с использованием клеток млекопитающих
US20200190200A1 (en) Methods of Producing Heterodimeric Antibodies
US20220347312A1 (en) Immunoconjugate Synthesis Method
US20250000995A1 (en) Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2024216089A1 (en) Anti-dectin-2 antibody combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230106

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508